Impact of alogliptin on coronary flow reserve evaluated by magnetic resonance imaging

Impact of alogliptin on coronary flow reserve evaluated by magnetic resonance imaging - Impact of alogliptin on coronary flow reserve evaluated by magnetic resonance imaging

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008238

Enrollment

Registered

2012-06-25

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with old myocardial infarction or angina pectoris

Interventions

alogliptin group control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with old myocardial infarction or angina pectoris

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes mellitus 2. Patient who already takes DPP4 inhibitors 3. Severe renal dysfunction (eGFR<30mL/min/1.73m2) 4. General contraindication to MRI (Claustrophobia, after pacemaker implantation etc.) 5. Patients who cannot hold breathe for about 10 seconds due to dyspnea 6. Contraindication to adenosine triphosphate infusion (asthma, advanced atrioventricular block etc.)

Design outcomes

Primary

Measure	Time frame
Coronary flow reserve evaluated by MRI	—

Secondary

Measure	Time frame
high-sensitivity CRP	—

Countries

Japan

Contacts

Public ContactShingo Kato

Kanagawa Cardiovascular and Respiratory Center Division of Cardiology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026